Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
21.41
+0.02 (0.09%)
Nov 20, 2026, 9:59 AM EST - Market open
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Amneal Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $24.29. The average 1-year stock price forecast is 13.45% higher than the current stock price, while the lowest is $20 (-6.59%) and the highest is $28 (+30.78%).
Price Target: $24.29 (+13.45%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 4 | 4 | 4 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Buy Reiterates $25 → $28 | Buy | Reiterates | $25 → $28 | +30.78% | Nov 9, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $23 → $25 | Buy | Maintains | $23 → $25 | +16.77% | Nov 5, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $24 → $25 | Buy | Maintains | $24 → $25 | +16.77% | Nov 4, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $27 | Buy | Maintains | $27 | +26.11% | Nov 3, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $21 → $24 | Buy | Maintains | $21 → $24 | +12.10% | Oct 29, 2026 |
Financial Forecast
Revenue This Year
3.21B
from 3.02B
Increased by 6.38%
Revenue Next Year
3.51B
from 3.21B
Increased by 9.21%
EPS This Year
1.06
from 0.83
Increased by 28.04%
EPS Next Year
1.23
from 1.06
Increased by 15.89%
EPS and Forward PE are based on non-GAAP adjusted numbers.